Tag archive for ‘Samsung Bioepis’
By news On Thursday, April 5th, 2018
0 Comments

AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023

(adsbygoogle = window.adsbygoogle || []).push({}); (Reuters) – AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off More...

By news On Tuesday, February 13th, 2018
0 Comments

Drug copies ready to take next bite out of Roche’s cancer sales

LONDON (Reuters) – European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies More...

By news On Friday, August 25th, 2017
0 Comments

Samsung, Biogen version of AbbVie’s Humira approved in Europe

(Reuters) – A biosimilar version of AbbVie Inc’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics, was approved by European Union regulators, the partners More...

By news On Monday, July 24th, 2017
0 Comments

Merck, Samsung Bioepis launch discounted U.S. Remicade alternative

NEW YORK/SEOUL (Reuters) – Merck & Co and South Korea’s Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson’s rheumatoid More...